Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | The ROCKstar study: belumosudil for chronic GvHD

Corey Cutler • 15 Jan 2021
ASH 2020
Belumosudil
ROCKstar

Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA, discusses the top-line results from the ongoing Phase II ROCKstar study (NCT03640481), investigating belumosudil for chronic graft-versus-host disease (cGvHD) after two or more prior lines of therapy. The study has found that treatment with belumosudil resulted in high overall response rates (ORR) which were durable and clinically meaningful. Additionally, belumosudil was well-tolerated, with limited and manageable adverse events. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Corey Cutler

1:26
Updates in transplantation at ASH 2020
Corey Cutler • 15 Jan 2021
1:26
RIC allogeneic HCT for high-risk MDS
Corey Cutler • 15 Jan 2021
The content of VJHemOnc is intended for healthcare professionals